TITLE

PEGylation of Interferon-β-1a

AUTHOR(S)
Kieseier, Bernd C.; Calabresi, Peter A.
PUB. DATE
March 2012
SOURCE
CNS Drugs;2012, Vol. 26 Issue 3, p205
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic properties. Numerous PEGylated therapeutics are currently available, all of which have at least comparable efficacy, safety and tolerability to their unmodified forms. A PEGylated form of interferon-β-1a (PEG-IFNβ-1a) is being developed to address an unmet medical need for safer, more effective and more convenient therapies for multiple sclerosis (MS). Phase I study data suggest that PEG-IFNβ-1a should provide patients with a first-line therapy with a more convenient dosing regimen while maintaining the established efficacy, safety and tolerability of presently available IFNβ-1a. The ongoing global ADVANCE phase Ill study will determine the clinical efficacy of PEG-IFNβ-1a in patients with relapsing MS.
ACCESSION #
74151956

 

Related Articles

  • Spotlight on Peginterferon-α-2a (40KD) in Chronic Hepatitis C. Perry, C.M.; Jarvis, B. // BioDrugs;2002, Vol. 16 Issue 3, p213 

    Peginterferon-α-2a (40KD) is a new ‘pegylated’ subcutaneous formulation of interferon-α-2a that has been developed to improve on the pharmacokinetic profile and therapeutic efficacy of interferon-α-2a. Peginterferon-α-2a (40KD) is produced by the covalent attachment of...

  • Immunomodulation: General.  // Multiple Sclerosis (13524585);Jan99 Supplement 1, Vol. 5 Issue 1, pS96 

    Presents summaries of several studies on immunomodulation. 'Practice of Interferon Î’ (IFN) Prescriptions in Switzerland 1995-1998,' by C. Lienert, et al; 'Patient-Centered Outcomes in a Regional MS Treatment Clinic,' by H.L. Ford, et al; 'The Cause of Non-Adherence to Disease-Course...

  • Therapy – immunosuppression.  // Multiple Sclerosis (13524585);Sep2005 Supplement, Vol. 11, p169 

    Discusses abstracts of studies about the role of immunosuppression in the treatment of multiple sclerosis, published in the October 2005 issue of the periodical "Multiple Sclerosis". "Comparison of Different Durations of High-Dose Intravenous Methylprednisolone Regimes in Moderate Relapses of...

  • Comparative Assessment of Immunomodulating Therapies for Relapsing-Remitting Multiple Sclerosis. Khan, O.; Zabad, R.; Caon, C.; Zvartau-Hind, M.; Tselis, A.; Lisak, R. // CNS Drugs;2002, Vol. 16 Issue 8, p563 

    The past decade has seen unprecedented advances in the development of disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS), a disease that has a worldwide prevalence of two million patients. Four agents with the ability to modulate the immune system are now being widely...

  • Preparation of monoPEGylated human interferon beta-1a: Optimization of the conditions for N-terminal PEGylation. Korzhavin, D.; Chernovskaya, T.; Efanov, Yu.; Rudenko, E.; Ivanov, R.; Pshenichnikova, A.; Shvets, V. // Applied Biochemistry & Microbiology;Dec2015, Vol. 51 Issue 7, p774 

    The recombinant human interferon (IFN) beta-1a was modified with polyethylene glycol (PEG). The reaction was performed with the use of activated linear butyraldehyde PEG derivative with a molecular weight of 30 kDa. As a result of the multifactorial experiment, the correlation between the...

  • Mountain View Pharmaceuticals Receives European Patent on Potential Long-Acting Drug for Multiple Sclerosis.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that Mountain View Pharmaceuticals Inc. has received European Patent for its Polyethylene Glycol (PEG) conjugates of interferon-beta-1b for the treatment of multiple sclerosis. It mentions that the company has developed PharmaPEG which is less antigenic and less immunogenic....

  • INTERFERONS, BETA.  // Davis's Drug Guide for Nurses, 9th edition;2005, p556 

    Provides information on interferons, beta, an anti-multiple sclerosis agent. Indications; Therapeutic effects; Pharmacokinetics; Contraindications and precautions; Side effects.

  • Therapy – immunomodulation – Part II.  // Multiple Sclerosis (13524585);Sep2005 Supplement, Vol. 11, p152 

    Discusses abstracts of studies about the role of immunomodulation in the treatment of multiple sclerosis, published in the October 2005 issue of the periodical "Multiple Sclerosis". "FTY720 Exposure/Efficacy Relationship in a 6-Month Phase 2 Study in Patients With Relapsing MS," by J. Kovarik...

  • Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. Paul, Friedemann; Waiczies, Sonia; Wuerfel, Jens; Bellmann-Strobl, Judith; Dörr, Jan; Waiczies, Helmar; Haertle, Mareile; Wernecke, Klaus D.; Volk, Hans-Dieter; Aktas, Orhan; Zipp, Frauke // PLoS Clinical Trials;Apr2008, Vol. 5 Issue 4, Special section p1 

    Background: Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible beneficial impact of statins on MS. Methodology/Principal Findings: Safety, tolerability and effects on disease activity of atorvastatin given alone or in combination with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics